iBio, Inc.
NASDAQ Capital MarketTotal Valuation
iBio, Inc. carries a market capitalization of 20.68M, placing it among publicly traded companies globally. Its enterprise value stands at -6.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.68M |
| Enterprise Value | -6.84M |
Share Statistics
iBio, Inc. currently has 34.54M shares outstanding.
| Shares Outstanding | 34.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 573.62, and the price-to-book ratio stands at 0.85.
| PE Ratio | N/A |
| PS Ratio | 573.62 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | -8.18 |
| P/OCF Ratio | -7.97 |
Enterprise Valuation
| EV / Sales | 565.97 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
iBio, Inc. maintains a current ratio of 11.88, meaning it holds 11.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.00, indicating elevated leverage, while an interest coverage ratio of -195.06 demonstrates limited ability to service its debt obligations.
| Current Ratio | 11.88 |
| Quick Ratio | 11.50 |
| Debt / Equity | 3.00 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | -195.06 |
Financial Efficiency
| Return on Equity (ROE) | -62.09 |
| Return on Assets (ROA) | -52.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
iBio, Inc.'s stock has gained approximately 56.88623% over the past 52 weeks. The 50-day moving average sits at 1.45, while the 200-day moving average is 1.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | 56.88623% |
| 50-Day Moving Average | 1.45 |
| 200-Day Moving Average | 1.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, iBio, Inc. generated 300,000.00 in revenue and converted that into -27.61M in net income, yielding earnings per share of -0.30. EBITDA reached -27.89M, while operating income came in at -28.96M.
| Revenue | 300,000.00 |
| Gross Profit | N/A |
| Operating Income | -28.96M |
| Pretax Income | -27.61M |
| Net Income | -27.61M |
| EBITDA | -27.89M |
| EBIT | -28.96M |
| Earnings Per Share (EPS) | -0.30 |
Balance Sheet
iBio, Inc. holds 74.80M in cash and equivalents against 2.33M in total debt, resulting in a net debt position of -47.63M. Total book value stands at 77.54M, with working capital of 70.75M providing operational flexibility.
| Cash & Cash Equivalents | 74.80M |
| Total Debt | 2.33M |
| Net Debt | -47.63M |
| Equity (Book Value) | 77.54M |
| Book Value Per Share | 2.24 |
| Working Capital | 70.75M |
Cash Flow
iBio, Inc. produced -21.60M in operating cash flow over the past twelve months. After subtracting -560,000.00 in capital expenditures, free cash flow totaled -22.16M - equivalent to -0.24 per share.
| Operating Cash Flow | -21.60M |
| Capital Expenditures | -560,000.00 |
| Free Cash Flow | -22.16M |
| FCF Per Share | -0.24 |
Margins
iBio, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -9,653.00 and net profit margin of -9,202.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -9,653.00 |
| Pretax Margin | -9,202.00 |
| Profit Margin | -9,202.00 |
| EBITDA Margin | -9,298.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -139.91 |
| FCF Yield | -12.23 |
Stock Splits
iBio, Inc.'s most recent stock split took place on November 29, 2023 with a 20:1 split ratio.
| Last Split Date | 11/29/2023 |
| Split Ratio | 20:1 |
Scores
iBio, Inc. posts an Altman Z-Score of -1.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.29 |